User Name Password

back to homepage

Objective Archives
2008: Oct | Sep | Aug | Jul | Jun | May | Apr | ...

Silverback Media (SBMP; SVD.F) - delisting
Objective Comment, Mar 31, 2008

Read More

Great Western Minerals (GWG.V) - PEAR delayed to include more fruitful opportunities
Objective Comment, Mar 28, 2008

Read More

Immersion Technologies (ITI.L) - first half results
Objective Comment, Mar 28, 2008

Read More

Arana Therapeutics (AAH.L) - the emergence of a therapeutic antibody powerhouse
Objective Report, Mar 26, 2008
Arana Therapeutics has emerged from the merger of Peptech and Evogenix with a significant, proprietary antibody technology platform, a broad pipeline of potential drugs focused on cancer and Autoimmune Inflammatory Diseases (AIID), and a strong cash position. We believe that it represents a significantly strengthened investment proposition for its current and future shareholders. 
Read More

Adanac Molybdenum (AUA.TO) - suppliers file undisputed liens against Ruby Creek; Adanac fund raising continues
Objective Comment, Mar 20, 2008

Read More

Arana Therapeutics (AAH.L) - ART621 entering PII trial in psoriasis
Objective Comment, Mar 19, 2008

Read More

Playfair Mining (PLY.V) - a beneficiary of China's impact on the tungsten market
Objective Report, Mar 18, 2008
The tungsten market is facing a paradigm shift as China directs its supply to support its rapidly expanding economy. Playfair has several Canadian tungsten projects that will benefi t from further price increases to help meet world demand for the metal. 
Read More

SilverCrest Mining (SVL.L) - Macquarie Bank commits to SilverCrest
Objective Comment, Mar 05, 2008

Read More

TiRex Resources (TXX.V) - encouraging assay from Mirdita first drill hole
Objective Comment, Mar 04, 2008

Read More

Soho Resources (SOH.V) - latest assays confirm significant but complex mineralisation
Objective Comment, Mar 04, 2008

Read More

SIGN UP NOW FOR OBJECTIVE'S STOCK RESEARCH - IT'S FREE!

Objective, Independent, Experienced.
Research you can trust!

Yes! Subscribe me for the latest stock research from Objective.
Email address
My Password
My information:
First Name
Family Name
Title:
Job title:
Job function:
Industry:
I am a:
 
To receive occasional printed reports complete your mailing address:
 
Company Name (if any)
Address
 
 
City
Postcode/Zip
Country

Please Read Objective's Terms of Use.

Objective Capital's Contact Information
Partnership, sales and product inquiries: marketing@objectivecapital.co.uk
Media services and conference requests: PR@objectivecapital.co.uk
Subscription and customer service issues: service@objectivecapital.co.uk
Comments or opinions on our analysis: analysis@objectivecapital.co.uk

By mail: 2nd floor, 145 St John Street, London EC1V 4PY, United Kingdom
Sales & Marketing: 11-12 Tokenhouse Yard, London EC2R 7AS, United Kingdom
ph +44-(0)870-080 2965 fax +44-(0)870-116 0839

About Us | Contact Us
Latest Analysis | Register Free | Archives
 
Copyright 2004 Objective Capital. All rights reserved.
Terms of Use | Privacy Policy | Disclaimer